AZ's Seroquel receives additional approval

The FDA has approved AstraZeneca's Seroquel for depressive episodes associated with bipolar disorder. The drug is already approved to treat manic episodes and is now the only therapy to treat both depressive and manic episodes associated with bipolar disorder. "Treating acute bipolar disorder with a single medication may help patients adhere to their medication regimen," said John Patterson, executive director of development for AstraZeneca, in a press release.

- see this press release [1] for more

PLUS: Schering-Plough has received approval for Noxafil Oral Suspension
for the treatment of oropharyngeal candidiasis (OPC), including infections
refractory to itraconazole and/or fluconazole. Just last month, the FDA approved the therapy for preventing fungal infections [2] in leukemia patients. Report [3]

ALSO: GlaxoSmithKline and Flamel Technologies' once-a-day Coreg has received approval from the FDA for hypertension, post-myocardial infarction left ventricular dysfunction, and heart failure. Release [4]

AND: Altana Pharma [5] has gained FDA approval for Omnaris nasal spray. Report [6]